Q-omics provides the consensus-scored MIR200CHG profile across patient tissues and cancer cell-line models. MIR200CHG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR200CHG is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MIR200CHG RNA expression shows 14,239 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where MIR200CHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR200CHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR200CHG survival associations across molecular data types. MIR200CHG RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR200CHG RNA expression–survival associations across cancer types. High MIR200CHG expression shows unfavorable associations in SKCM, KIRP, ACC and UVM, but favorable associations in BLCA and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR200CHG RNA expression.
This table summarizes MIR200CHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR200CHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR200CHG shows lower tumor expression in KIRC and KIRP and higher tumor expression in BLCA, BRCA, COAD and THCA. The KIRC box plot shows higher MIR200CHG RNA expression in normal versus tumor tissue (log2 FC = −2.986, t-test p < 0.001).
This table shows molecular features associated with MIR200CHG in patient tissues and cancer cell lines. In patient samples, MIR200CHG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
